FDA Approves TAGRISSO — AstraZeneca Pharmaceuticals LP

AstraZeneca received FDA approval for TAGRISSO (osimertinib), enhancing its lung cancer portfolio and strengthening its position in the targeted therapy market. This commercial entity's provision of a first-line treatment option underscores its growing dominance in the oncology space and drives significant competitive pressure on rival pharmaceutical firms.